Metabolic and Endocrine Effects of Combination of Metformin and DPP-4 Inhibitor Saxagliptin Compared to Saxagliptin or Metformin XR Monotherapy in Patients With PCOS and Impaired Glucose Regulation: A Single-blinded Randomized Pilot Study

Trial Profile

Metabolic and Endocrine Effects of Combination of Metformin and DPP-4 Inhibitor Saxagliptin Compared to Saxagliptin or Metformin XR Monotherapy in Patients With PCOS and Impaired Glucose Regulation: A Single-blinded Randomized Pilot Study

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs Saxagliptin/metformin (Primary) ; Metformin; Saxagliptin
  • Indications Hyperglycaemia
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms BMS-AZPCOS
  • Most Recent Events

    • 31 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 22 Aug 2016 Planned End Date changed from 1 Aug 2016 to 1 Nov 2016.
    • 22 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top